PL378122A1 - Zastosowanie palonosetronu do leczenia pooperacyjnych nudności i wymiotów - Google Patents

Zastosowanie palonosetronu do leczenia pooperacyjnych nudności i wymiotów

Info

Publication number
PL378122A1
PL378122A1 PL378122A PL37812204A PL378122A1 PL 378122 A1 PL378122 A1 PL 378122A1 PL 378122 A PL378122 A PL 378122A PL 37812204 A PL37812204 A PL 37812204A PL 378122 A1 PL378122 A1 PL 378122A1
Authority
PL
Poland
Prior art keywords
vomiting
palonosetron
operative nausea
treating post
post
Prior art date
Application number
PL378122A
Other languages
English (en)
Polish (pl)
Inventor
Luigi Baroni
Alberto Macciocchi
Enrico Braglia
Riccardo Braglia
Original Assignee
Helsinn Healthcare S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL378122(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare S.A. filed Critical Helsinn Healthcare S.A.
Publication of PL378122A1 publication Critical patent/PL378122A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL378122A 2003-02-18 2004-02-18 Zastosowanie palonosetronu do leczenia pooperacyjnych nudności i wymiotów PL378122A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44834203P 2003-02-18 2003-02-18

Publications (1)

Publication Number Publication Date
PL378122A1 true PL378122A1 (pl) 2006-03-06

Family

ID=32908576

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378122A PL378122A1 (pl) 2003-02-18 2004-02-18 Zastosowanie palonosetronu do leczenia pooperacyjnych nudności i wymiotów

Country Status (31)

Country Link
US (1) US20060074101A1 (enExample)
EP (2) EP2258367A3 (enExample)
JP (1) JP2006517944A (enExample)
KR (1) KR101113087B1 (enExample)
CN (1) CN1750822A (enExample)
AT (1) ATE490774T1 (enExample)
AU (1) AU2004212704B2 (enExample)
BR (1) BRPI0407549A (enExample)
CA (1) CA2515946C (enExample)
CU (1) CU23587B7 (enExample)
CY (1) CY1111312T1 (enExample)
DE (1) DE602004030424D1 (enExample)
DK (1) DK1596862T3 (enExample)
EA (1) EA013836B1 (enExample)
EC (1) ECSP055970A (enExample)
ES (1) ES2357769T3 (enExample)
GE (1) GEP20104908B (enExample)
HR (1) HRP20050709A2 (enExample)
IS (1) IS7983A (enExample)
MX (1) MXPA05008757A (enExample)
MY (1) MY143789A (enExample)
NO (1) NO20054296L (enExample)
NZ (1) NZ541862A (enExample)
PL (1) PL378122A1 (enExample)
PT (1) PT1596862E (enExample)
SI (1) SI1596862T1 (enExample)
TW (1) TWI355936B (enExample)
UA (1) UA96254C2 (enExample)
UY (1) UY28193A1 (enExample)
WO (1) WO2004073714A1 (enExample)
ZA (1) ZA200506580B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045615A1 (en) * 2002-11-15 2004-06-03 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
EP2363117B1 (en) * 2006-01-27 2015-08-19 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
NZ569984A (en) * 2006-01-27 2011-06-30 Eurand Inc Drug delivery systems comprising weakly basic drugs and organic acids
ME01949B (me) * 2006-10-24 2010-08-31 Meke kapsule koje sadrže palonosetron hlorovodonik koji ima poboljšanu stabilnost i bioraspoloživost
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US20090155363A1 (en) * 2007-12-14 2009-06-18 Todd Maibach Methods for oral administration of active drugs
JP5547065B2 (ja) 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
US20100143461A1 (en) * 2008-12-08 2010-06-10 Ben-Zion Solomon Palonosetron formulation
ES2432618T3 (es) * 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
SI2432467T1 (en) 2009-05-20 2018-06-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) ANTAGONIST RECEPTOR SEROTONINA 5-HT3 FOR THE USE IN THE TREATMENT OF LEASE VESTIBULAR DISEASES
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20120253046A1 (en) 2009-11-13 2012-10-04 Helsinn Healthcare S.A. Palonosetron metabolites
ES2559475T3 (es) 2009-11-18 2016-02-12 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos de origen central
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
WO2014004126A1 (en) 2012-06-26 2014-01-03 Fleming C Andrew Treating postoperative nausea and vomiting
KR20150073866A (ko) 2013-12-23 2015-07-01 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
ES2975016T3 (es) 2016-04-14 2024-07-02 Sensorion (+)-Azasetrón para uso en el tratamiento de trastornos del oído
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
US11433021B2 (en) 2018-01-12 2022-09-06 Orion Corporation Palonosetron for the treatment or prevention of nausea and vomiting
CN108703960A (zh) * 2018-07-25 2018-10-26 无锡鑫连鑫生物医药科技有限公司 一种帕洛诺司琼缓释微球及其制备方法和使用方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
EP0498466B1 (en) 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Indazole-3-carboxamide and -3-carboxylic acid derivatives
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US4707484A (en) 1986-11-25 1987-11-17 Hoffmann-La Roche Inc. Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
PL166272B1 (pl) * 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
US5189041A (en) 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5137893A (en) 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5491148A (en) 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5492914A (en) 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
AU4551499A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-HT3 receptors
WO2000024375A1 (en) * 1998-10-27 2000-05-04 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
US6196963B1 (en) * 1999-03-02 2001-03-06 Medtronic Ave, Inc. Brachytherapy device assembly and method of use
AU2003237657A1 (en) * 2002-05-24 2003-12-12 Epidauros Biotechnologie Ag Means and methods for improved treatment using "setrones"
WO2004045615A1 (en) * 2002-11-15 2004-06-03 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) * 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron

Also Published As

Publication number Publication date
EP2258367A2 (en) 2010-12-08
NO20054296D0 (no) 2005-09-16
EA013836B1 (ru) 2010-08-30
AU2004212704B2 (en) 2009-10-01
DE602004030424D1 (de) 2011-01-20
MXPA05008757A (es) 2006-05-31
AU2004212704A1 (en) 2004-09-02
MY143789A (en) 2011-07-15
WO2004073714A1 (en) 2004-09-02
CA2515946A1 (en) 2004-09-02
HK1076402A1 (en) 2006-01-20
GEP20104908B (en) 2010-03-10
JP2006517944A (ja) 2006-08-03
NZ541862A (en) 2008-04-30
BRPI0407549A (pt) 2006-02-14
TWI355936B (en) 2012-01-11
UY28193A1 (es) 2004-09-30
KR20050121671A (ko) 2005-12-27
ATE490774T1 (de) 2010-12-15
EA200501318A1 (ru) 2006-02-24
DK1596862T3 (da) 2011-03-28
KR101113087B1 (ko) 2012-02-15
CN1750822A (zh) 2006-03-22
CA2515946C (en) 2008-12-02
IS7983A (is) 2005-08-15
UA96254C2 (uk) 2011-10-25
HRP20050709A2 (en) 2005-12-31
TW200418474A (en) 2004-10-01
US20060074101A1 (en) 2006-04-06
EP1596862A1 (en) 2005-11-23
SI1596862T1 (sl) 2011-03-31
NO20054296L (no) 2005-11-17
PT1596862E (pt) 2011-03-15
CU23587B7 (es) 2010-10-30
CY1111312T1 (el) 2015-08-05
EP1596862B1 (en) 2010-12-08
EP2258367A3 (en) 2011-07-13
ECSP055970A (es) 2006-01-16
ES2357769T3 (es) 2011-04-29
ZA200506580B (en) 2006-06-28

Similar Documents

Publication Publication Date Title
HRP20050709A2 (en) Use of palonosetron treating post-operative nausea and vomiting
UA87473C2 (en) Muscarinic acetycholine receptor antagonists
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
WO2008069889A3 (en) Methods of treating hemolytic anemia
MY144753A (en) Muscarinic acetylcholine receptor antagonists
TW200745112A (en) Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
SG170033A1 (en) Octahydro-pyrrolo[3,4-b] pyrrole derivatives and their use as histamine-3 receptor ligands
AU2003272285A1 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
AU2003270166A1 (en) Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression
WO2009155054A3 (en) 5-ht3 receptor modulators, methods of making, and use thereof
PL369889A1 (en) Anticholinergic agents, method for producing the same and use thereof as medicaments
GB0426313D0 (en) Therapeutic agents
CA2505990A1 (en) Palonosetron for the treatment of chemotherapy-induced emesis
BRPI0412629A (pt) método de tratamento de disfunção ocular em mamìferos
IL164606A0 (en) Novel compounds
TW200519108A (en) Muscarinic acetylcholine receptor antagonists
TW200519109A (en) Muscarinic acetylcholine receptor antagonists
WO2006011811A3 (en) Radicals and their use as paramagnetic agents in a dynamic nuclear polarisation process
MXPA04004477A (es) Antagonistas del neuropeptido neuroquinina-1(nk1).
TW200700065A (en) Phenanthroindolizidine alkaloids
TW200606161A (en) Muscarinic acetylcholine receptor antagonists
UA83203C2 (uk) Тіазол-(бі)циклоалкілкарбоксаніліди, засіб на їх основі та застосування для боротьби з небажаними мікроорганізмами
MX2007016373A (es) Compuestos de piridil y piridonil estereoisomericos y metodos para el tratamiento de trastornos gastrointestinales y del sistema nervioso central.
WO2006016192A3 (en) Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia
MXPA04004075A (es) Compuesto y metodo para tratamiento de vejiga hiperactiva.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)